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Objectives. This study sought to 1) assess in vivo release of
platelet-derived growth factor (PDGF) and basic fibroblast
growth factor (bFGF) into the coronary circulation after vascular
injury in human subjects; and 2) evaluate mitogenic effects of
PDGF and bFGF on the patient’s own vascular smooth muscle
cells (VSMCs).
Background. Circumstantial evidence suggests involvement of
PDGF and bFGF peptides in the neointimal response to vascular
injury. To date, no study has shown biologically active growth
factors within the coronary circulation after vascular injury in
human subjects.
Methods. In 18 patients, plasma PDGF AB, platelet factor 4
(PF4) and beta-thromboglobulin (beta-TG) levels were measured
in coronary sinus blood obtained before and up to 30 min after
angioplasty. In five patients undergoing atherectomy, coronary
sinus serum was added to cultured VSMCs derived from atherec-
tomy tissue to assess the mitogenic potential of the serum.
Mitogenicity attributable to PDGF and bFGF was determined
using neutralizing antibodies to these factors. PDGF A, PDGF B
and bFGF were localized within the atherectomy tissue using
immunocytochemical analysis.
Results. Before angioplasty, PDGF AB, PF4 and beta-TG levels
were elevated threefold in patients scheduled for angioplasty
compared with those in control patients (p < 0.01). Within 5 min
of angioplasty, PDGF AB levels increased twofold and returned
toward preangioplasty levels at 30 min; PF4 and beta-TG levels
remained elevated. Serum obtained at 30 min after atherectomy
showed a sixfold increase in mitogenicity compared with preath-
erectomy serum (p 5 0.01). This increase in mitogenicity was
reduced by 20%, 40% and 65% in the presence of neutralizing
antibodies to PDGF, bFGF and PDGF 1 bFGF, respectively.
PDGF A, PDGF B and bFGF were visualized within the intima of
the atherectomy tissue.
Conclusions. The change in plasma PDGF level is consistent
with first-phase release of PDGF after vascular injury. The
increase in mitogenicity of serum suggests that PDGF and bFGF
are biologically active.
(J Am Coll Cardiol 1997;29:1536–41)
©1997 by the American College of Cardiology
Neointimal proliferation and subsequent restenosis is a com-
mon outcome after treatment of obstructive coronary artery
lesions with percutaneous transluminal coronary angioplasty
(PTCA) or atherectomy in human subjects (1,2). This neoin-
tima is composed of proliferating vascular smooth muscle cells
(VSMCs), platelets, organized thrombus and extracellular
matrix (3). After arterial injury, release of mitogenic and
chemotactic factors from intracellular and extracellular ele-
ments within the lesion and from aggregated platelets on the
damaged intimal surface is thought to initiate the neointimal
response (4).
A number of studies suggest that growth factors mediate
neointimal proliferation of VSMCs, but the mechanisms have
not been clarified. Immunocytochemical and in situ hybridiza-
tion techniques have demonstrated (5–7) increased expression
of platelet-derived growth factor (PDGF) and basic fibroblast
growth factor (bFGF) within atherosclerotic lesions. In the rat
balloon injury model (8,9), neutralizing antibodies to PDGF or
bFGF have successfully inhibited neointimal formation. Tra-
pidil, a competitive PDGF receptor blocking agent, has signif-
icantly reduced the rate of restenosis after angioplasty in both
From the Department of Medicine and Centre for Research in Vascular
Biology, Department of Anatomical Sciences, University of Queensland; and
Department of Cardiology, Prince Charles Hospital, Brisbane, Queensland,
Australia. This study was presented in part at the Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand, Canberra, Australian Capital
Territory, August 1995. Dr. Caplice was supported by the National Heart
Foundation of Australia, Canberra, Australian Capital Territory and the Prince
Charles Hospital Private Practice Research and Education Trust Fund, Brisbane,
Queensland, Australia.
Manuscript received April 15, 1996; revised manuscript received February
14, 1997, accepted February 26, 1997.
Address for correspondence: Dr. Malcolm J. West, Department of Medicine,
Level B1, Pathology, Prince Charles Hospital, Rode Road, Chermside, Brisbane,
Queensland 4032, Australia.
JACC Vol. 29, No. 7
June 1997:1536–41
1536
©1997 by the American College of Cardiology 0735-1097/97/$17.00
Published by Elsevier Science Inc. PII S0735-1097(97)00076-4
animal and human studies (10,11). However, despite these
data, the contribution of different cellular and extracellular
elements in the injured lesion to the dynamics of growth factor
release after angioplasty in humans is uncertain. Furthermore,
the relative importance of different growth factors in lesion
development, and the time during which mitogen release
occurs, is unknown.
The purpose of the present study was to search for evidence
of growth factor release in human subjects that would equate
with the first phase of the response to injury pattern in the rat
balloon injury model (4). To identify the existence and biologic
significance of first-phase growth factor release in human
subjects, we devised two experiments.
In the first of these we assessed plasma levels of PDGF AB
together with the platelet activation markers platelet factor 4
(PF4) and beta-thromboglobulin (beta-TG), collected from
the coronary sinus before and after angioplasty. In a second
series of experiments, we collected coronary sinus serum
before and after atherectomy. The mitogenic potential of each
patient’s serum was assessed by measuring its proliferative
effect on cultured VSMCs derived from the same patient’s
tissue obtained at the time of atherectomy. Using neutralizing
antibodies to PDGF and bFGF, the relative contribution of
growth factor to patient serum mitogenicity was determined.
Immunocytochemical analysis was used to localize PDGF A,
PDGF B and bFGF within recovered atherectomy tissue.
Methods
Subjects. The first study group included 18 patients with
single-vessel coronary artery disease (15 men, 3 women; mean
[6SD] age 54 6 12 years, range 35 to 73) referred for PTCA
and 10 control patients (8 men, 2 women; mean age 57 6 12
years, range 39 to 70) with angiographically normal coronary
arteries. The second study group included five male patients
(mean age 45 6 8 years, range 36 to 58) undergoing directional
atherectomy for proximal left anterior descending coronary
artery stenosis. After femoral sheath access, all patients re-
ceived 10,000 to 15,000 U of heparin intraarterially. All
patients were taking aspirin and antianginal medications (beta-
adrenergic blocking agents, calcium channel blocking agents
and nitrates). Patients with diseases that might influence
platelet function, such as severe anemia, chronic renal failure,
recent unstable angina and recent myocardial infarction, were
excluded from the study. All subjects had given written in-
formed consent in accordance with hospital ethical guidelines.
Coronary sinus sampling. A 7F Cournand catheter was
placed through the left antecubital vein into the coronary
sinus. After 30 min, a control blood sample was collected.
Blood was again taken at 5, 10, 15, 20 and 30 min after
successful angioplasty or atherectomy with the balloon or
atherectomy device withdrawn into the guiding catheter. Three
milliliter samples of blood were obtained at each time point
and those samples not obtained smoothly were discarded.
Plasma and serum preparation. Blood for plasma samples
was collected in ice-cold glass tubes (Becton-Dickinson) con-
taining citrate, theophylline, adenosine and dipyridamole.
Blood for serum samples was allowed to clot in SST clot
activator tubes (Becton Dickinson Vacutainer Systems, Mey-
lan, France). Plasma and serum was separated and centrifuged
at 3,000 rpm for 30 min at 4°C and then immediately frozen
and stored at 280°C.
Plasma growth factor and platelet marker assays. Plasma
assays of PDGF AB, PF4 and beta-TG were performed within
1 month of collection using commercially available enzyme-
linked immunosorbent kits (PDGF AB: R. & D. Systems; PF4:
Behring Diagnostics, Marburg, Germany; beta-TG: Diagnos-
tica Stago, Asierses-sur-Seine, France).
VSMC culture and serum mitogenicity. Tissue obtained
during atherectomy was explanted on 35-mm fibronectin-
coated (10 mg/cm2) plastic culture plates in the presence of
Dulbecco’s modified Eagles’ medium (DMEM) and 10% fetal
calf serum. Medium was changed every fourth day. After 4
weeks, VSMCs were subcultured using trypsin (0.125%).
VSMCs were identified by their “hill and valley” morphology
and positive staining with alpha-smooth muscle actin (HHF
35) antibody.
VSMCs between passages 2 and 6 were used for mitoge-
nicity experiments and were seeded at a density of 1 3 104
cells/well in a 96-well plate. Cells were allowed to attach
overnight and then growth arrested for 48 h in serum-free
medium. Cells were then released from growth arrest using 5%
(vol/vol) of the patient’s own serum in DMEM. The wells were
incubated with the following culture media: 1) DMEM 1 5%
patient serum from samples obtained before and at previously
described times after atherectomy (n 5 5); 2) DMEM 1 5%
patient serum 1 a neutralizing antibody (R. & D. Systems) to
PDGF (10 mg/ml) (n 5 5); 3) DMEM 1 5% patient serum 1
a neutralizing antibody (R. & D. Systems) to bFGF (10 mg/ml)
(n 5 3); and 4) DMEM 1 5% patient serum 1 neutralizing
antibodies to both PDGF and bFGF (n 5 3). The dose of
PDGF and bFGF antibodies used was 10 times that required to
produce neutralization according to the manufacturer. Anti-
bodies were stated to be specific for PDGF and bFGF and with
minimal cross-reactivity with other cytokines. Cells were also
incubated with pooled control serum from human donors.
3H-Thymidine (0.5 mCi/well) was pulsed between 24 and 48 h
after release from growth arrest. Cells from triplicate wells
were harvested with trypsin at 48 h onto glass fiber filters. The
filters were dried overnight, immersed in scintillation fluid and
Abbreviations and Acronyms
beta-TG 5 beta-thromboglobulin
bFGF 5 basic fibroblast growth factor
DMEM 5 Dulbecco’s modified Eagle’s medium
EGF 5 epidermal growth factor
PF4 5 platelet factor 4
PDGF 5 platelet-derived growth factor
PTCA 5 percutaneous transluminal coronary angioplasty
VSMCs 5 vascular smooth muscle cells
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analyzed in a beta-counter. Counts were expressed as cpm/
well.
Immunocytochemical analysis. Frozen sections (5 mm)
were obtained from one atherectomy tissue fragment from
each patient. Tissue was lightly fixed in cold acetone and
incubated overnight at 4°C with primary antibodies to PDGF
A, PDGF B (Genzyme), bFGF (Santa Cruz) and mouse
immunoglobulin G (Amersham) over a concentration range
of 0.1 to 2.0 mg/ml in phosphate buffer containing 1% bo-
vine serum albumin. A secondary anti-mouse biotinylated
system with streptavidin– horseradish peroxidase and 3,3-
diaminobenzidine for visualization was used. Sections were
counterstained with hematoxylin.
Statistics. Results are expressed as mean value 6 SEM.
Clinical and angiographic characteristics were compared using
a Wilcoxon signed rank test. Two-way analysis of variance with
repeated measures and the Scheffe´ S test were used to test
differences between levels of plasma PDGF AB, PF4 or
beta-TG at each time point after angioplasty and the prean-
gioplasty level (12). An unpaired t test was used for compari-
son between plasma values for control subjects and for
angioplasty-group patients before angioplasty. For serum mi-
togenicity experiments, analysis of variance and the Scheffe´ S
test were used to test differences between 3H-thymidine incor-
poration at each time point. An unpaired t test was used for
comparison between pooled donor serum values and preath-
erectomy values; p , 0.05 was considered significant for all
statistical tests.
Results
Clinical data. A summary of clinical data is shown in Table
1. There was no significant difference in coronary risk factors
between control, angioplasty and atherectomy groups. No
subject had diabetes mellitus. In subjects undergoing PTCA,
stenosis severity was reduced from 84 6 2% to 22 6 2%. In
those undergoing atherectomy, stenosis was reduced from
84 6 2% to 16 6 5%.
Coronary sinus plasma PDGF AB, PF4, beta-TG. Plasma
PDGF A and B, PF4 and beta-TG concentrations after angio-
plasty are shown in Figure 1. Control patients had significantly
lower (p , 0.01) plasma levels of PDGF AB, PF4 and beta-TG
than angioplasty-group patients before PTCA, indicating a low
level of platelet activation in the control group. After angio-
plasty, there was a twofold increase in PDGF AB levels that
peaked at 5 min and returned to pre-PTCA levels by 30 min.
Both PF4 and beta-TG continued to be elevated during the
30 min after angioplasty, although both levels dropped over
time.
Coronary sinus serum mitogenicity. The mitogenicity of
serum obtained from atherectomy-group patients and from
human donors is shown in Figure 2. The mitogenicity of serum
obtained before atherectomy, measured by VSMC 3H-
thymidine incorporation, was low and similar to that of pooled
donor serum (1,942 6 275 vs. 1,092 6 42 cpm/well, n 5 5 for
each group). However, serum obtained at each time point after
atherectomy produced a sequential sixfold increase in 3H-
thymidine incorporation (3,250 6 378 cpm/well at 5 min vs.
11,603 6 324 cpm/well at 30 min, p 5 0.01, n 5 5).
Table 1. Clinical and Angiographic Characteristics of Study Groups
Control
Group
Angioplasty
Group
Atherectomy
Group
Age (yr) 51 6 12 51 6 12 45 6 8
Men/women 8/2 15/3 5/0
Risk factors
Smoking 7 16 5
Hypertension 4 6 1
Hypercholesterolemia 4 9 3
Diseased artery
None 10 — —
LAD — 12 5
LCx — 12 —
RCA — 3 —
Data presented are mean value 6 SD or number of patients. LAD 5 left
anterior descending coronary artery; LCx 5 left circumflex coronary artery;
RCA 5 right coronary artery.
Figure 1. Time course of changes in coronary sinus plasma levels of
PDGF AB (top), PF4 (middle) and beta-TG (bottom) in patients
undergoing coronary angioplasty. Control patients were those who had
no evidence of coronary artery disease at routine angiography. Results
shown are mean value 6 SE. *p , 0.05 versus preangioplasty level by
analysis of variance. BTG 5 beta-thromboglobulin.
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Effect of neutralizing antibodies to PDGF and bFGF on
mitogenicity of serum. Neutralizing antibody to PDGF caused
a 20% reduction in the mitogenicity of serum obtained at each
time point after atherectomy. Neutralizing antibody to bFGF
caused a 40% reduction in the mitogenicity of the same serum
after atherectomy. In the presence of PDGF and bFGF
neutralizing antibodies combined, the mitogenicity of serum
obtained at each time point after atherectomy was reduced by
;65% (Fig. 2).
Localization of PDGF A and B and bFGF within plaque.
PDGF A and B staining was seen in atherectomy specimens
from all patients. PDGF A staining was localized to the
subendothelial and intimal cells, with little staining of the
endothelium. PDGF B staining was strongly localized to
endothelial cells as well as to the cytoplasm of some subendo-
thelial cells. There was also extracellular staining of PDGF B.
bFGF staining was prominent in the subendothelial region of
all plaque specimens (Fig. 3).
Discussion
Coronary sinus plasma PDGF AB and platelet activation
markers. The first observation from our study was that base-
line pre-PTCA plasma levels of PDGF AB and platelet
activation markers were elevated in angioplasty-group patients
with coronary disease compared with those in control subjects.
After PTCA a further twofold elevation in plasma PDGF AB
was seen, which returned to pre-PTCA levels 30 min after
PTCA. High plasma PF4 and beta-TG levels were maintained
after angioplasty compared with control levels. Repeated
sampling of blood in control patients over the same time
period as that in patients undergoing angioplasty was not
possible. The measures of platelet activation after angioplasty
differ in this study compared with those of Scharf et al. (13)
who demonstrated a drop in PF4 levels and an elevation in
beta-TG levels after angioplasty. However, in the study group
of Scharf et al., preangioplasty levels of platelet activation were
very low. Because PF4 is known to bind more strongly to
matrix components (i.e., heparan sulfate proteoglycans) within
the vessel wall than PDGF, it is unlikely that PDGF AB and
PF4 are equivalent in their distribution between tissue and
plasma compartments downstream from the angioplasty site.
Therefore, PF4 levels in the coronary sinus cannot be linked to
the extent of platelet release of PDGF AB at the site of injury.
However, sustained elevation of beta-TG in our study suggests
that ongoing platelet activation contributed to PDGF AB
release. Release of PDGF AB from other sources, such as the
vessel wall, cannot be excluded.
Coronary sinus serum mitogenicity and source of serum
mitogens. The main observation from our study was that the
mitogenicity of serum derived from the coronary sinus over the
first 30 min after atherectomy increased sixfold compared with
preatherectomy or control donor serum. The mitogenic effect
of each patient’s serum on his or her own VSMCs in culture
was due predominantly to PDGF and bFGF mitogens. Autol-
ogous serum was used for culture experiments because in our
experience single-patient serum was toxic to VSMCs derived
from other human subjects. Pooled control donor serum does
not have these problems and has been used in a previous study
(14). Autologous serum coincubated with the patient’s own
VSMCs may also better mimic conditions in vivo. PDGF A,
PDGF B and bFGF were demonstrated using immunocyto-
chemical analysis in the subendothelial and endothelial regions
of plaque obtained at the time of atherectomy, and these
findings are consistent with other immunocytochemical studies
(6,7).
In the present study, growth factor release may have been
from activated platelets, as indicated by our observations in the
first series of experiments or from damaged endothelial (15)
and intimal smooth muscle cells (16). Serum was used instead
of plasma for the mitogenic assay because plasma produced
coagulation of the VSMC culture medium. Serum derived
from clotted blood contains products of maximal platelet
activation that are present in each of the samples. It is
therefore likely that the increased serum mitogenicity after
intervention is from a source other than platelets, possibly the
vessel wall. Crowley et al. (16) recently demonstrated, using
immunoblot analysis and neutralization studies, that mechan-
ically injured bovine VSMCs in culture immediately released
biologically active growth factors bFGF, PDGF and epidermal
growth factor (EGF), presumably from preformed stores in the
cell cytoplasm. Heparin, which was given to all patients under-
going atherectomy during the procedure, is also known to
release PDGF and bFGF from matrix-bound stores, especially
Figure 2. 3H-Thymidine incorporation of human VSMCs obtained
from patients at the time of atherectomy, showing 3H-thymidine
incorporation (cpm/well) of cells exposed to 5% patient serum ob-
tained before and after atherectomy in the absence of any neutralizing
antibody (ab) (n 5 5) (solid circles); in the presence of a neutralizing
antibody to PDGF (10 mg/ml) (n 5 5) (open circles); in the presence
of a neutralizing antibody to bFGF (10 mg/ml) (n 5 3) (open
triangles); and in the presence of neutralizing antibodies to both
PDGF and bFGF (n 5 3) (solid triangles). Five percent pooled donor
serum was used as a control in each experiment. At 15, 20 and 30 min,
3H-thymidine incorporation for each treatment was significantly
greater than the preatherectomy value for the respective treatment
(p , 0.05 by analysis of variance). Results shown are mean value 6 SE.
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in injured vessels without an endothelium (17–20). PDGF may
also be released from endothelial cells by proteases such as
thrombin, which may be a mechanism for active mobilization
of growth factors by injured endothelium (15).
Our data provide evidence of first-phase growth factor
release in human subjects after vascular injury. PDGF and
bFGF appear to be released in sufficient quantities within the
first 30 min after atherectomy to be strongly mitogenic to each
patient’s VSMCs. It is possible that the neutralizing antibodies
used blocked autocrine PDGF or bFGF produced by the
explanted smooth muscle cells. The low level of mitogenicity
obtained with control serum-treated cells suggests that auto-
crine growth factor production was small and that postatherec-
tomy serum-derived growth factors provided the bulk of the
increased mitogenic stimulus. The mitogenic effects of serum
collected after atherectomy were not completely blocked by
antibodies to PDGF and bFGF, suggesting that mitogens other
than PDGF and bFGF are present. Factors that might have
contributed to this include mitogens, such as EGF and trans-
forming growth factor-beta, as well as nonpeptide factors, such
as serotonin and adenosine diphosphate, which are known to
be present in the coronary sinus blood after angioplasty (21).
These factors may have synergistic effects maximizing the
cellular growth response to locally released mitogens (21). A
synergism between increased levels of these factors and auto-
crine PDGF or bFGF, or both, cannot be fully excluded.
Study limitations. There are limitations in the interpreta-
tion of the results of our study. In control subjects it was not
felt ethically justifiable to examine the effects of coronary sinus
catheterization over a similar time period to that in patients
undergoing angioplasty. Strict time controls are therefore
lacking in this study. We assumed that serum obtained from
the coronary sinus reflects events occurring at the site of
atherectomy. It is likely the degree of platelet degranulation
and growth factor release at the site of injury was underesti-
mated by measurement of the concentration of mitogen down-
stream in the coronary sinus. Increased flow within the coro-
nary circulation after stenosis dilation may cause these
substances to be further diluted downstream. We measured the
spillover of mitogens into coronary sinus blood that were either
released as a consequence of the injury or were weakly bound
within the atherosclerotic plaque and washed out as a result of
exposure after the atherectomy. We can only speculate that
similar or greater concentrations of growth factors are avail-
able locally at the site of injury or within the vessel wall.
Figure 3. Micrographs of 5-mm frozen sections of atherectomy frag-
ments showing positive brown staining for PDGF A, PDGF B and
bFGF antibodies visualized with a peroxidase–3,3-diamino-benzidine
system. A, PDGF A staining subendothelial cells with nuclear, cyto-
plasmic and extracellular staining (4003). B, PDGF B staining local-
izing to the endothelial and subendothelial region with intracellular
and extracellular staining (4003). C, bFGF staining in the subendo-
thelial region of the intima (2003). D, Control section with mouse
immunoglobulin G at similar titer (2003). All five patients had similar
staining patterns for each of the growth factors. All sections were
lightly counterstained with hematoxylin. L 5 lumen.
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Assessment of serum mitogenicity after atherectomy involved
measurement of DNA synthesis during serum incubation with
VSMCs for 48 h. Although the index of serum mitogenicity
remained elevated at 30 min after atherectomy, it is not
possible to determine whether these mitogens are elevated in
vivo for sufficiently long periods to initiate VSMC proliferation
at the lesion site. Continued sampling of coronary sinus blood
over a longer period would help to address this question.
Withdrawal of blood through a long catheter may cause
platelet activation (22). The use of heparin in our study and the
low levels of platelet activation markers in control plasma
suggest that significant platelet activation was not induced
during sampling.
Conclusions. Characterization of coronary sinus plasma
containing elevated levels of PDGF AB after angioplasty and
serum showing strong mitogenic properties after atherectomy
is consistent with first-phase growth factor release as described
in the balloon injury animal model. Early release of biologi-
cally active growth factors, even in small quantities, may act
locally in a synergistic fashion to produce a significant mito-
genic signal (16). The present study provides a basis for the
recently described reduction in restenosis rate after PTCA
after the use of the PDGF receptor blocking drug trapidil (11).
It indicates that a combined approach to blocking both PDGF
and bFGF may have added benefit in reducing neointimal
proliferation.
We thank Diana Steenberg for preparation of the manuscript and Maria Kay for
assistance in sample collection.
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